The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerBusiness Wire • 08/08/23
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023Business Wire • 08/02/23
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical TrialsBusiness Wire • 07/27/23
UroGen Pharma Announces the Appointment of James Robinson to its Board of DirectorsBusiness Wire • 07/25/23
Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney PreservationBusiness Wire • 07/10/23
Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde AdministrationBusiness Wire • 06/20/23
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 06/09/23
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 05/11/23
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023Business Wire • 05/04/23
Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to DeclineZacks Investment Research • 05/02/23
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic EvaluationBusiness Wire • 05/01/23
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal PelvisBusiness Wire • 04/30/23
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate DevelopmentsBusiness Wire • 03/16/23
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023Business Wire • 03/09/23
Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder CancerBusiness Wire • 02/15/23
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial CancerBusiness Wire • 01/11/23